GMED
Globus Medical
74.50$
+0.3%
vs. previous close
Closing price · As of: Sep 25, 2026
Statements
Balance Sheet
All figures as a percentage of total assets in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| 66.8% | 65.3% | 55.4% | 57.5% | 48.5% | 44.9% | 48.9% | 44.2% | 47.4% | 37.7% | 41.5% | 40.1% | |
| 11.7% | 7.2% | 7.2% | 11.0% | 10.7% | 12.8% | 14.3% | 9.9% | 7.2% | 9.2% | 14.9% | 9.9% | |
| 32.5% | 33.7% | 31.3% | 34.7% | 26.1% | 20.3% | 25.4% | 22.7% | 21.5% | 10.2% | 16.9% | 10.5% | |
| 11.5% | 10.4% | 10.3% | 11.8% | 11.1% | 10.6% | 8.8% | 8.5% | 10.5% | 9.9% | 11.0% | 14.0% | |
| 12.9% | 12.6% | 12.1% | 10.1% | 10.1% | 12.8% | 13.6% | 12.1% | 14.4% | 16.7% | 12.6% | 14.3% | |
| 9.9% | 13.8% | 13.4% | 13.3% | 13.2% | 13.2% | 12.9% | 11.3% | 11.7% | – | – | – | |
| 7.6% | 11.0% | 11.4% | 11.5% | 9.5% | 8.4% | 9.3% | 9.2% | 9.5% | 28.2% | 27.3% | 27.1% | |
| 4.9% | 4.0% | 6.7% | 7.3% | 6.7% | 5.1% | 5.2% | 3.5% | 3.1% | 18.2% | 15.1% | 14.1% | |
| 16.8% | 14.2% | 10.3% | 10.3% | 8.9% | 8.5% | 10.3% | 11.0% | 11.1% | 21.4% | 20.5% | 13.8% | |
| 12.7% | 9.9% | 8.6% | 8.6% | 7.4% | 7.3% | 7.2% | 7.2% | 7.7% | 7.7% | 16.3% | 9.4% | |
| – | – | – | – | 0.3% | 4.9% | 5.3% | 4.8% | 0.1% | 0.2% | 8.6% | 0.3% | |
| 3.0% | 1.9% | 1.9% | 2.3% | 2.0% | 1.6% | 1.1% | 1.1% | 1.7% | 1.1% | 1.4% | 1.9% | |
| 0.0% | 0.0% | 0.0% | 0.0% | – | – | – | – | – | 8.2% | – | – | |
| 83.2% | 85.8% | 89.7% | 89.7% | 91.1% | 91.5% | 89.7% | 89.0% | 88.9% | 78.6% | 79.5% | 86.2% | |
| 58.5% | 62.9% | 67.8% | 68.3% | 68.6% | 68.4% | 62.2% | 61.0% | 59.7% | 22.4% | 22.0% | 26.2% | |
| 13.6% | 11.5% | 10.4% | 9.1% | 7.8% | 6.7% | 6.0% | 5.3% | 4.9% | 2.3% | 2.6% | 2.6% |
Data as of: September 25, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.